Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 264

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 264
---
|-------:|:--|
| Operating expenses:                                                                      |     |      |     |                    |        |   |     |      |        |   |
| Research and development expenses                                                        |     | 12a  |     | $                  |   (806 | ) |     | $    |   (971 | ) |
| General and administrative expenses                                                      |     | 12b  |     |                    | (1,125 | ) |     |      |   (436 | ) |
| Operating loss                                                                           |     |      |     |                    | (1,931 | ) |     |      | (1,407 | ) |
| Financial expense, net                                                                   |     | 12c  |     |                    | (2,201 | ) |     |      |    (42 | ) |
| Net loss and comprehensive loss                                                          |     |      |     | $                  | (4,132 | ) |     | $    | (1,449 | ) |
| Basic and diluted net loss per share                                                     |     | 2l   |     | $                  |  (60.2 | ) |     | $    |  (23.0 | ) |
| Weighted average number of shares used in computing basic and diluted net loss per share |     |      |     |                    | 69,403 |   |     |      | 64,879 |   |

<div align='center'>The accompanying notes are an integral part of
the financial statements.

F-19</div>

REGENTIS BIOMATERIALS LTD.

STATEMENTS OF TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT

U.S. dollars in thousands (except share data)

|                                                 |     | Convertible      
 preferred shares 
 Number           |           |     | Amount |        |     | Ordinary shares 
 Number          |        |     | Amount |    |   |     | Additional paid-in 
 capital            |       |     | Accumulated 
 deficit     |         |   |     | Total shareholders’ 
 deficit             |         |   |
|:------------------------------------------------|:----|:-----------------|----------:|:----|:-------|-------:|:----|:----------------|-------:|:----|:-------|:---|:--|:----|:-------------------|------:|:----|:------------|:--------|:--|:----|:--------------------|--------:|:--|
| Balance